Multiple sclerosis in the real world: A systematic review of fingolimod as a case study

Multiple Sclerosis

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study

PLoS One.

Izquierdo G, Damas F, Páramo MD, Ruiz-Peña JL, Navarro G

doi: 10.1371/

Multiple Sclerosis

Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study

Neurology.

Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M

doi: 10.1212/WNL.

Multiple Sclerosis

Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE)

doi: 10.1111/ene.13594.

Multiple Sclerosis

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

J Neurol.

Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group

doi: 10.1007/s00415-018-9070-x.

Multiple Sclerosis

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Ther Adv Neurol Disord.

Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S

doi: 10.1177/

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Aging and Cognitive FunctionsMultiple Sclerosis

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

J Neurol.

Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, Centonze D, Pozzilli C, Saccà F, Bergh FT, Bartezaghi M, Turrini R, Filippi M; Golden Study Group

doi: 10.1007/s00415-017-8642-5.

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

Multiple Sclerosis

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

J Neurol Neurosurg Psychiatry.

Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H

doi: 10.1136/jnnp-2018-319831.

Related content

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study

Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study

Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE)

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

Vaccination Readiness in Multiple Sclerosis

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis